The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 08, 2015

Filed:

Jun. 13, 2012
Applicants:

David M. Donovan, Baltimore, MD (US);

Igor V. Abaev, Obelensk, RU;

Inventors:

David M. Donovan, Baltimore, MD (US);

Igor V. Abaev, Obelensk, RU;

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12N 9/80 (2006.01); C12N 15/52 (2006.01); C12N 1/11 (2006.01); C07K 14/005 (2006.01); A01P 1/00 (2006.01); A61L 2/16 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C12N 9/80 (2013.01); C07K 14/005 (2013.01); C12N 15/52 (2013.01); C12Y 305/01028 (2013.01); A61K 38/00 (2013.01); A61L 2/16 (2013.01); C12N 2795/10322 (2013.01); C12N 2795/10332 (2013.01); C12N 2795/10333 (2013.01);
Abstract

is notorious for developing resistance to virtually all antibiotics to which it is exposed. Staphylococcal phage 2638A endolysin is a peptidoglycan hydrolase that is lytic forwhen exposed externally, making it a new antimicrobial candidate. It shares a common protein organization with over 40 other staphylococcal peptidoglycan hydrolases: a CHAP endopeptidase domain, a mid-protein amidase 2 domain and a C-terminal SH3b cell wall binding domain. It is the first phage endolysin reported with a cryptic translational start site between the CHAP and amidase domains. Deletion analysis indicates that the amidase domain confers most of the lytic activity and requires the full SH3b domain for maximal activity. It is common for one domain to demonstrate dominant activity over another; however, the phage 2638A endolysin is the first to show high amidase domain activity dominant over the N-terminal CHAP domain, an important finding for targeting novel peptidoglycan bonds.


Find Patent Forward Citations

Loading…